2017
The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R, Dhruva SS, Fox ER, Ross JS. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States. Journal Of Managed Care & Specialty Pharmacy 2017, 23: 1066-1076. PMID: 28944731, PMCID: PMC10397719, DOI: 10.18553/jmcp.2017.23.10.1066.Peer-Reviewed Original ResearchMeSH KeywordsCommerceDrug ApprovalDrug IndustryHumansPharmaceutical PreparationsPrescription DrugsTherapeutic EquivalencyUnited StatesUnited States Food and Drug AdministrationConceptsUnapproved Drugs InitiativeClinical evidenceAverage wholesale priceFDA approvalPrescription drugsNew clinical trial evidenceMedian shortage durationClinical trial evidenceNew clinical evidenceDrug shortagesNumber of drugsEvidence of safetyUtah Drug Information ServiceHealth-System Pharmacists
2016
Therapeutic Substitution—Should It Be Systematic or Automatic?
Ross JS. Therapeutic Substitution—Should It Be Systematic or Automatic? JAMA Internal Medicine 2016, 176: 776. PMID: 27158769, DOI: 10.1001/jamainternmed.2016.2271.Commentaries, Editorials and Letters
2013
When Choosing Statin Therapy: The Case for Generics
Green JB, Ross JS, Jackevicius CA, Shah ND, Krumholz HM. When Choosing Statin Therapy: The Case for Generics. JAMA Internal Medicine 2013, 173: 229-232. PMID: 23303273, DOI: 10.1001/jamainternmed.2013.1529.Commentaries, Editorials and LettersMeSH KeywordsCardiovascular DiseasesChoice BehaviorDrugs, GenericDyslipidemiasEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsTherapeutic Equivalency
2012
Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise
Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise. JAMA Internal Medicine 2012, 172: 724-730. PMID: 22493409, PMCID: PMC3636774, DOI: 10.1001/archinternmed.2012.187.Commentaries, Editorials and LettersChemistry, PharmaceuticalDrugs, GenericFenofibrateHypolipidemic AgentsLaboratoriesMarketingTherapeutic Equivalency